Progyny, Inc.

PGNY • Medical - Healthcare Information Services

$25.94

▼ -0.67 (-2.52%)

Current price

EarningsLatest report: Mar 31, 2026

BALANCED PROFILENeutralConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Mixed profile. The company is not automatically unattractive, but valuation, growth, or balance-sheet evidence does not yet justify a stronger signal.

Market Cap

$2.20B

Growth

7.4%

Cash Flow

5/5

Trend

Stable

Evidence

Positive revenue growth · 28.1%Positive free cash flow · 2.25Consistent free cash flow · 5/5Manageable debt level · 0.05Healthy liquidity · 2.73

Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 7, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$25.94

Change-2.52%

Shares Out84.76M

Market Cap$2.20B

Enterprise Value$1.98B

52W Range16.10 - 28.75

Beta1.04

P/E32.48

P/S1.70

P/B4.85

P/FCF10.23

EV/Sales1.53

Price$25.94

Change-2.52%

Shares Out84.76M

Market Cap$2.20B

Enterprise Value$1.98B

52W Range16.10 - 28.75

Beta1.04

P/E32.48

P/S1.70

P/B4.85

P/FCF10.23

EV/Sales1.53

EV/EBITDA18.35

EV/FCF9.23

Earnings Yield3.08%

FCF Yield9.77%

Dividend Yield0.00%

Gross Margin23.63%

Oper. Margin6.62%

Profit Margin4.54%

Debt/Eq0.05

Current Ratio2.73

Quick Ratio2.73

Revenue 5Y7.40%

Target$35.13

Target Upside35.43%

Target Median$35.50

Target Range30.00 - 40.00

Volume1.24M

Avg Volume1.51M

EPS Surprise0.03

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

33/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

95/100

Price Attractiveness

Cheap or expensive today

62/100

Why this score▼

Positive revenue growth · 28.1%Positive free cash flow · 2.25Consistent free cash flow · 5/5Manageable debt level · 0.05Healthy liquidity · 2.73Expensive earnings multiple · 37.4

Analyst view

Analyst sentiment and price target

PGNY

Analyst sentiment

Based on 20 analyst votes · 2026-09-05

85/100

Bullish

Hold

Bearish

Price Target

2026-06-24

Low

$27.00

Mean

$30.33

Median

$30.00

High

$35.00

Company Overview

IPO: 10/25/2019

Industry: Medical - Healthcare Information Services

P/B i: 4.85

Debt / Equity i: 0.05

Operating Margin: 6.62%

Net Margin: 4.54%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.05

Current Ratio: 2.73

Quick Ratio: 2.73

Status: Good

Insider Transactions

Recent executive and insider activity

Clapp Geoffrey

Transaction: 06/17/2026

SELL

Change

-819

Price

$26.60

Filing

06/23/2026

Type

SELL

Swartz Allison

Transaction: 06/04/2026

SELL

Change

-599

Price

$25.08

Filing

06/05/2026

Type

SELL

Livingston Mark S.

Transaction: 06/04/2026

SELL

Change

-599

Price

$25.50

Filing

06/05/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Clapp Geoffrey	SELL	-819	$26.60	06/17/2026	06/23/2026
Swartz Allison	SELL	-599	$25.08	06/04/2026	06/05/2026
Livingston Mark S.	SELL	-599	$25.50	06/04/2026	06/05/2026
Anevski Peter	SELL	-5,361	$25.12	06/03/2026	06/05/2026
Swartz Allison	SELL	-1,199	$25.02	06/03/2026	06/05/2026
Livingston Mark S.	SELL	-1,082	$25.12	06/03/2026	06/05/2026
Swartz Allison	SELL	-2,398	$25.46	05/28/2026	06/01/2026
GORDON KEVIN K	SELL	-2,526	Not reported	05/27/2026	05/29/2026
MORRIS DEBRA L	BUY	+5,660	Not reported	05/21/2026	05/26/2026
MORRIS DEBRA L	BUY	+3,203	$24.69	05/21/2026	05/26/2026
Scott Cheryl	BUY	+5,660	Not reported	05/21/2026	05/26/2026
Scott Cheryl	BUY	+27,119	$24.69	05/21/2026	05/26/2026
Payson Norman	BUY	+5,660	Not reported	05/21/2026	05/26/2026
Payson Norman	BUY	+3,203	$24.69	05/21/2026	05/26/2026
Park Jeffrey G	BUY	+5,205	$24.69	05/21/2026	05/26/2026
Park Jeffrey G	BUY	+7,924	Not reported	05/21/2026	05/26/2026
HOLSTEIN ROGER C	BUY	+6,792	Not reported	05/21/2026	05/26/2026
HOLSTEIN ROGER C	BUY	+4,003	$24.69	05/21/2026	05/26/2026
GORDON KEVIN K	BUY	+6,792	Not reported	05/21/2026	05/26/2026
GORDON KEVIN K	BUY	+30,373	$24.69	05/21/2026	05/26/2026

About the Company

Progyny, Inc.

Progyny, Inc. functions as a benefits management corporation, dedicated to providing specialized solutions for fertility and broader family-building initiatives to employers throughout the United States. Its core fertility offering is characterized by a distinctive benefits plan architecture, paired with personalized, white-glove member support services and access to a meticulously chosen network of top-tier fertility specialists. Additionally, the company presents Progyny Rx, an all-encompassing pharmacy benefits solution that ensures its members can readily acquire the essential medications for their treatments. Moreover, Progyny facilitates employer-sponsored reimbursement programs to support surrogacy and adoption journeys. The company, which was established in 2008 and has its main offices in New York City, previously operated as Auxogyn, Inc. before adopting the Progyny, Inc. moniker in 2015.

Source - link

Peers

ALVO GDRX OMCL OMDA PHR SDGR SEM TDOC TXG UFPT

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Progyny, Inc. to Present at the Wells Fargo Healthcare Conference

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced that its Chief Financial Officer Mark Livingston will present at the Wells Fargo 21st Annual Healthcare Conference in Boston, MA on Tuesday, September 8, 2026, at 11:00 a.m. ET.

GlobeNewsWire

Hsbc Holdings PLC Makes New $760,000 Investment in Progyny, Inc. $PGNY

Hsbc Holdings PLC acquired a new stake in shares of Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 26,394 shares of the company's stock, valued at approximately $760,000. Several other large investors have also

Defense World

23,600 Shares in Progyny, Inc. $PGNY Bought by Canada Pension Plan Investment Board

Canada Pension Plan Investment Board acquired a new stake in Progyny, Inc. (NASDAQ: PGNY) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 23,600 shares of the company's stock, valued at approximately $680,000. A number of other hedge funds and other

Defense World

Progyny, Inc. (NASDAQ:PGNY) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Progyny, Inc. (NASDAQ: PGNY - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen analysts that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating

Defense World

AWM Investment Company Inc. Purchases Shares of 220,000 Progyny, Inc. $PGNY

AWM Investment Company Inc. bought a new position in shares of Progyny, Inc. (NASDAQ: PGNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 220,000 shares of the company's stock, valued at approximately $6,343,000. AWM Investment Company Inc. owned about 0.29% of

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-07	0.256	0.29	0.034
2026-02-26	0.147	0.15	0.003
2025-11-06	0.39	0.45	0.06
2025-08-07	0.44	0.48	0.04
2025-05-08	0.45	0.48	0.03
2025-02-27	0.37	0.42	0.05
2024-11-12	0.37	0.4	0.03
2024-08-06	0.36	0.43	0.07
2024-05-09	0.14	0.39	0.25
2024-02-27	0.11	0.32	0.21
2023-11-07	0.12	0.16	0.04
2023-08-03	0.1	0.15	0.05